最新发布
Switch Bio partners with Bayer to advance ‘switchable’ tech for biofertilizers
Switch Bioworks—a startup engineering nitrogen fixing microbes that colonize plant roots before switching on ammonia pro…
Undecimal raises $18M to take siRNA beyond the liver
The spinout from Eleven Therapeutics operates in Cambridge, England, and Tel Aviv, Israel. 4BIO Capital and IQ Capital co-led the round, joined by Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital.
LVMH beauty sales hold steady in Q3 as Sephora drives retail growth
LVMH (Moët Hennessy Louis Vuitton) has reported organic growth in its Perfumes & Cosmetics business and Selective Retailing, led by Sephora, in Q3 2026.
Roche’s China shopping spree continues with $1B Rona obesity pact
Why it matters: The Swiss drugmaker is expanding its search for treatments that reduce fat while preserving lean mass. The agreement also puts Roche alongside Arrowhead Pharmaceuticals and GSK in pursuing ALK7, a target that could complement GLP-1 drugs.
Fine fragrances boost Givaudan beauty sales
Givaudan’s organic sales outpaced market expectations by almost twofold in Q3. The company’s like-for-like sales grew 8.6% in the quarter, compared to analyst expectations of 4.7%.
🎥 ClimateCrop bets on starch ‘off switch’ to improve crop performance
Neutralizing the “off switch” for starch production in plants could be the key to unlocking higher yields and boos…
Enodia lands $500M Pfizer deal to target proteins at the point of synthesis
Why it matters: The targeted protein degradation field is gaining momentum, and this Pfizer-Enodia collaboration offers another example of how large pharmaceutical companies are increasingly willing to place strategic bets on this emerging therapeutic category.
Elicera’s CAR-T clears detectable lymphoma in eight patients
Why it matters: The patients had heavily pretreated B-cell lymphoma and no remaining curative treatment options. Three patients had relapsed after earlier CAR-T treatment. Two of those patients responded to ELC-301, including one who achieved a complete metabolic response.
It’s time to take action on cybersecurity in agrifood
Startups, investors, and media outlets like this one love to talk about the potential benefits of digitizing agrifood. F…
Desentum secures €28M for faster allergy immunotherapy
Why it matters: Desentum wants to shorten treatment that typically requires years of repeated allergen exposure. Its lead candidate, DM-101PX, produced a strong antibody response after 10 weekly injections in Phase 1. The next test is whether that response translates into fewer allergy symptoms.